Are you collecting
the right core data?
To understand patient outcomes
we study real people
Primary data can identify rare adverse outcomes and customize risk management plans. Our non-interventional and cohort studies go to the source - real people - to collect targeted and potentially sensitive data not always available on electronic databases. Assessing real use risks, we help to resolve safety concerns, validated by treating physicians.
FINDING BEST ANSWERS IN THE DATA JUNGLE
TO GENERATE TRUE EVIDENCE YOU NEED THE RIGHT DATA SOURCES
Advances in Real-World Evidence methodologies give us access to more data than ever before, shifting the challenge from collection to interpretation. Amid the jungle of data, we help clients make the right assumptions and choose the best sources to answer health product and care questions optimally.
How do you navigate the changing landscape?
We keep your regulatory submission on track
Change is frequent in the regulatory environment. We are adept in adjusting across borders and differing requirements. Our project managers, with significant medical and epidemiology experience, develop and evaluate the study design and protocols, communicating with you at every step. The EURAS study design method is at the heart of our work.
ZEG’s methodology emerged from our study of ‘The Third Generation Pill Crisis’ of 1996-2002. Relieving international safety fears, the study found the increased incidence of deep vein thrombosis (DVT) was partly an artefact of inherent biases. The EURAS-OC study, with our partners, was a turning point for ZEG, and its design has been used in many Post Authorization Safety Studies since.
updated